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Introduction
Development of lung-targeting ligands has been an important focus of drug delivery
for the treatment of respiratory diseases to increase drug concentrations in the lung
and minimizing toxicity. Currently, two major forms of lung-targeting drugs have
been developed: 1) inhaled drugs, which are directly delivered to the respiratory tract,
thereby improving pharmacological effects of therapy and minimizing unwanted
systemic side effects (such as inhaled broncholytics, inhaled anti-inflammatory
drugs, and inhaled vasodilators)1–3 and 2) passive lung-targeting drugs, which are
likely localized in pulmonary capillary mechanical retention (eg, levofloxacin
liposome).4–6 However, inhaled drugs have shown only limited efficacy against airway
diseases, due to the barriers of respiratory structures and cooperation of patients.7
Furthermore, clinical application of passive lung-targeting drugs is also hampered
by the high retention of the reticuloendothelial system, such as the liver and spleen.
Therefore, there is an urgent need to develop more effective lung-targeting drugs
or delivery ligands.
An antibody may recognize its antigen in vivo with high affinity and specificity.
Based on this principle, active targeting drugs that consist of antibody ligands and
nanoparticles via chemical conjugation have increased drug concentrations in the
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Abstract: Lung-targeting drugs are thought to be potential therapies of refractory lung diseases
by maximizing local drug concentrations in the lung to avoid systemic circulation. However,
a major limitation in developing lung-targeted drugs is the acquirement of lung-specific ligands.
Pulmonary surfactant protein A (SPA) is predominantly synthesized by type II alveolar epithelial
cells, and may serve as a potential lung-targeting ligand. Here, we generated recombinant rat
pulmonary SPA (rSPA) as an antigen and immunized an alpaca to produce two nanobodies
(the smallest naturally occurring antibodies) specific for rSPA, designated Nb6 and Nb17.
To assess these nanobodies’ potential for lung targeting, we evaluated their specificity to lung
tissue and toxicity in mice. Using immunohistochemistry, we demonstrated that these anti-rSPA
nanobodies selectively bound to rat lungs with high affinity. Furthermore, we intravenously
injected fluorescein isothiocyanate-Nb17 in nude mice and observed its preferential accumulation
in the lung to other tissues, suggesting high affinity of the nanobody for the lung. Studying acute
and chronic toxicity of Nb17 revealed its safety in rats without causing apparent histological
alterations. Collectively, we have generated and characterized lung-specific nanobodies, which
may be applicable for lung drug delivery.
Keywords: nanobodies, rSPA, phage-nanobody library, VHH, lung-targeting drugs
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targeting tissue and decreased distribution in unrelated
organs (especially in the liver and spleen) compared to their
nontargeting counterparts.8–10 Because certain cancer cells
overexpress growth-factor receptors or other molecules that
can be easily targeted, recent studies have largely focused on
tumor-targeting drugs.11–13 However, to date, the development
of active lung-targeting drugs has been hampered by the lack
of specific ligands for lung tissue.
Studies have shown that pulmonary surfactant protein
A (SPA) is predominantly produced by alveolar epithelial
type II cells and rarely expressed elsewhere.14 In recent
years, SPA has become a commonly used marker of the
lung for diagnosis of lung diseases.15,16 Therefore, SPA
may serve as an attractive lung-targeting molecule for the
development of active lung-targeting drugs. Particularly,
targeting SPA by an antibody may be a viable approach.
We have successfully developed dexamethasone liposomes with active lung-targeting distribution by linking
anti-SPA polyclonal antibodies (SPA-poly-ant) with a
dexamethasone (DXM) nanoliposome (NLP) surface
(SPA-DXM-NLP).17 The concentration of the SPA-DXMNLP complex in the lung is approximately fivefold greater
than the free DXM control initially and reached 40-fold
greater at 12 hours postinjection. Also, administration of
SPA-DXM-NLP significantly attenuates lung injury in
animal models. However, using full-size antibodies like
anti-SPA-poly-ant for ligands is not ideal, because of their
high molecular weight, strong immunogenicity, and low
tissue penetration.18
To overcome this problem, recent studies have illustrated
that the serum of Camelidae contains some special antibodies
that are naturally devoid of light chains, termed heavy-chain
antibodies (HcAbs).19 HcAbs can recognize their cognate
antigens by a single variable-domain, referred to as VHH.
Due to the nanometer-scale size of VHH, Ablynx (a company
focusing on therapeutic applications of camelid antibodies)
renamed VHHs Nanobodies® (Nbs).20,21 Nanobodies are the
smallest naturally occurring intact antigen-binding domains
of antibodies identified to date. In addition, benefiting from
their small size, nanobodies are of higher affinity, more
soluble, and more stable than other antibody fragments, such
as F(ab’)2 or single-chain antibodies.22 Nanobodies also have
better tissue penetration and less immunogenicity,23 which
may be promising for application in the antitumor and antiinfection fields.24–26
In this study, we report the development of novel antirSPA nanobodies and the assessment of in vitro and in vivo
targeting ability and toxicity.
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Materials and methods
Materials
GenScript constructed the recombinant plasmid pGEX-4T-1-rSPA containing the rSPA gene sequence (Nanjing,
People’s Republic of China [PRC]). The plasmid (pET-44a,
pET-30a, pCANTAB5E), Escherichia coli BL21, Ex Taq
deoxyribonucleic acid (DNA) polymerase, deoxynucleotide
triphosphates (dNTPs), and DNA-purification kit were
purchased from Tiangen Biotech (Beijing, PRC). A DNA
ligation Kit, DNA markers, and restriction endonucleases
were obtained from Takara Biotech (Dalian, PRC). Our
laboratory prepared the rabbit antialpaca IgG antibody.
Isopropyl-β-d-thiogalactoside (IPTG), horseradish peroxidase (HRP)-conjugated goat antirat IgG, and anti-His
monoclonal antibody were provided by Beijing Biosynthesis
Biotechnology (Beijing, PRC). Quartz crystal microbalance
(QCM) measurements were performed using a Q-Sense D300
instrument with 5 MHz quartz crystals deposited with gold
electrodes (14 mm diameter) on a single side of the surface
(Q-Sense, Gothenburg, Sweden). All other reagents were
at least analytical grade for this study, and were purchased
from Sigma-Aldrich (St Louis, MO, USA).

Animals
BALB/c-nu/nu female mice, approximately 4 weeks old and
18–20 g, were housed in specific pathogen-free conditions.
Female Sprague Dawley rats, approximately 4–5 weeks old
and 100±10 g, were purchased from Shanghai SLAC Laboratory Animal Co Ltd (laboratory animal production license
SCXK [Hu]). The Institutional Animal Ethics Committee for
Experimentation on Animals of Tongji University approved
all animal experiments.

Preparation of rSPA antigen
A 245 bp fragment of the rSPA gene (verified via the National
Center for Biotechnology Information website) was optimized
based on E. coli codon usage, synthesized by GenScript,
and subcloned into the pET-44a expression vector. Then,
the recombinant plasmid pET-44a-rSPA was transformed
into BL21(DE3) E. coli bacteria. The transformants were
inoculated in Lysogeny broth medium containing 70 μg/mL
ampicillin and incubated overnight at 37°C/250 rpm.
Expression was induced with different concentrations of
IPTG (0.5, 0.8, and 1 mM) in various induction times and
temperatures (2, 4, and 8 hours and 25°C, 30°C, 37°C).
The expressed protein was examined by 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis gel and then purified
by 1.0 mL nickel nitrilotriacetic acid resin (Qiagen, Valencia,
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CA, USA). Immunoblotting and enzyme-linked immunosorbent assay (ELISA) using anti-rSPA-poly-ant evaluated the
purified protein, and GST protein was used as a control.

Immunization and construction of
anti-rSPA-VHH libraries

Immunization and construction of anti-rSPA VHH libraries
have been described in detail elsewhere.27–29 Briefly, a 2-yearold male alpaca was immunized weekly subcutaneously with
at least 2 mg rSPA antigen for a period of 5 weeks. Nodular
masses at the subcutaneous injection sites were observed after
each immunization to ensure that the immunization procedure
was performed appropriately. Blood was collected from the
jugular vein prior to each injection, and the sera were used
to monitor the immunization process, determined by indirect
ELISA. The serum antibody titers were determined by the
presence of a positive result at the highest possible dilution.
Fourteen days after the last immunization, peripheral blood
(200 mL) was collected and lymphocytes were isolated. Then,
ribonucleic acid (RNA) was extracted using a Pure RNA
Isolation Kit (Roche, Nutley, NJ, USA), and complementary
DNA (cDNA) was synthesized via a Revert Aid First-Strand
cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania). Nested
polymerase chain reaction was performed to amplify the VHH
fragments by using primers specific for HcAbs, which were
designed according to the constant region (CH2) of alpaca
HcAbs.30 The amplified VHH fragments were ligated into the
phagemid vector pCANTAB5E after being digested with
the SfiI restriction enzyme. Next, the ligated vector was
subsequently transformed into TG1 E. coli cells. The VHH
repertoire was expressed in phage particles after a rescue
procedure with the helper phage M13K07.

Panning and screening of anti-rSPAspecific nanobodies
The panning protocol was utilized as described elsewhere.27–29
Three consecutive rounds of panning using immunotubes that
were coated with rSPA antigen were used to enrich the antirSPA-VHH libraries. Individual colonies that were specific for
rSPA after the third round of panning were tested in a phage
ELISA. Briefly, clones were grown in 2× YT medium with
100 μg⋅mL−1 ampicillin and 0.1% glucose medium. They
were then infected with M13K07 helper phage and incubated
at 37°C for 30 minutes. Then, 50 μg⋅mL−1 kanamycin was
added and the clones amplified overnight at 37°C with
shaking. The cultured clones were next centrifuged, and
100 μL of supernatant containing the recombinant phage
particles was then added to rSPA precoated microtiter plate
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wells. After 2 hours’ incubation at 37°C, microtiter plate
wells were washed three times with phosphate-buffered
saline (PBS)-Tween 20 followed by the addition of antiM13 HRP conjugate (1/5,000). V HH phages that were
bound to rSPA were detected by adding 100 μL of HRP
substrate (KPL, Gaithersburg, MD, USA). After 15 minutes
of incubation, the reaction was stopped using 1 M H3PO4,
and absorption at 405 nm was measured. The unique VHH
genes of the clones that scored positive in phage ELISA were
selected for sequencing analysis.

Expression and purification of nanobodies
After sequence confirmation, the clones with higher affinity
were selected for prokaryotic expression. The production
and purification of the selected clones was described earlier.
Then, Western immunoblotting and ELISA confirmed the
biological activity of the purified protein. As the expression
vector contains His-tag, anti-His antibody was used as a
secondary antibody. At the same time, the purified protein
concentrations were measured by bicinchoninic acid assay.

Biophysical analyses of Nb17

First, Nb17 was adjusted to a concentration of 10 μg/mL
in PBS. A goat anti-rSPA-poly-ant was used as control.
Both were incubated at various temperatures (0°C, 10°C,
30°C, 50°C, 70°C, and 100°C) and at various pH values
(3.5, 6.5, 7.0, 7.3, 7.5, 8.0, and 8.5 for 2 hours). After incubation, Nb17 and rSPA-poly-ant were subsequently incubated
for 30 minutes at room temperature. To test antibody binding,
all samples were detected using the standard procedure as
described in the following. Nb17 and rSPA-poly-ant were
transferred to rSPA-coated microplates. After incubation for
1 hour, microplates were blocked to reduce a specific binding
with PBS containing 1% bovine serum albumin and 0.05%
Tween 80. Then, Nb17 and rSPA-poly-ant was used as the
second antibody. As the third step, goat antimouse conjugated
with HRP was used.

Immunohistochemistry
In order to determine the binding activity of the purified antirSPA nanobodies to SPA, we performed immunohistochemistry using the frozen sections of the lung, heart, liver, spleen,
kidney, and muscle tissue of rats. A goat anti-rSPA-poly-ant
was used as a positive control for the primary antibody.
The anti-rSPA nanobodies (Nb6 and Nb17) were used for
the experimental groups, while an unrelated nanobody was
used as the negative-control group. The secondary antibody
used in both the experimental and the negative-control
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groups was mouse anti-His monoclonal antibody, and in the
positive-control group, it was rabbit antigoat IgG.
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Analysis of binding ability by QCM
The binding ability of Nb17 to rSPA antigen was further
evaluated by QCM. The frequency change (∆f) is used to
measure the ability of protein–protein binding. The formula
of Sauerbrey - ∆f =-2.6×105 f0∆M/A - proved that for
nanobodies with gold substrate antigen binding, the better
the quality of the greater amount of change (∆M), the greater
the frequency, and the stronger the effect of protein binding.
In this formula, f0 means quartz-oscillator base frequency
(MHz), ∆f is frequency quartz-oscillator frequency-shift
value of the variable (Hz), ∆M is electrode material deposited
on the mass of the variable (g), A is the area of the working
electrode (cm2), and a negative number represents quality.
The procedures included 1) 0.1% mercaptopropionic acid at
electrode surfaces to produce a carboxylic acid-terminated
monolayer, 2) activation by 5 mg/mL ethylene dichloride and
10 mg/mL N-hydroxysuccinimide to generate a stable acyl
amino ester intermediate for 1 hour, and 3) adding 1 mL Nb17
and control nanobody to gold substrates. At 37°C 1-hour
incubation under continuous monitoring, working ranges
from 102 to 105 cells/mL with reproducibility 10% relative
standard deviation were obtained. The frequency change (∆f)
indicated the ability of protein–protein binding.

Analysis of targeting efficiency in vivo
Since there was a high degree of homology (95%) in the
amino acid sequence of SPA between the Sprague Dawley
rats and BALB/c-nu/nu female mice and it is much easier
to image mice, we next used nude mice (six for each group)
for in vivo imaging. The nude mice were randomly divided
to an experimental group (receiving Nb17) and a control
group (receiving a goat anti-rSPA-poly-ant), which were
labeled with fluorescein isothiocyanate (FITC). The free
FITC group were also assigned as controls. The experimental
group was intravenously injected with 10 μL FITC-Nb17
(1 mg/kg), and the control group with the same amount of
anti-rSPA-poly-ant, followed by imaging at multiple time
points (0 and 15 minutes, and 1, 2, 3, and 6 hours) using a
Xenogen small-animal in vivo imaging system (PerkinElmer,
Waltham, MA, USA). For the imaging experiments, all the
mice were first anesthetized with urethane.

Acute and chronic toxicity tests
Twenty Sprague Dawley female rats were randomly divided
into four groups: 1) the acute toxicity group, 2) the acute
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toxicity control group, 3) the chronic toxicity group, and
4) the chronic toxicity control group. The acute toxicity
group was intravenously injected with 10 mg/kg Nb17 and
monitored for 1 week. The acute-negative control group
was treated with the same volume of sterile normal saline.
The chronic toxicity group was intravenously injected
with Nb17 at a dose of 0.1 mg/kg Nb17 once daily for
3 months. The chronic-negative control group was treated
with the same volume of saline daily for 3 months. Liver
and kidney functions were then analyzed. Tissue injury
of rat lung, liver, spleen, and kidney tissues stained with
hematoxylin and eosin was investigated at the indicated
time points.

Statistical analysis
All experimental data were statistically analyzed using
SPSS 16.0 software. Continuous variables are expressed as
mean ± standard deviation. Experimental data were analyzed by one-way analysis of variance, followed by least
significant difference t-tests, when significant differences
existed among groups. P-values of less than 0.05 were considered statistically significant.

Results
Preparation of antigen
The recombinant vector pET-44a-rSPA containing a 245amino acid fragment of SPA was created as described in the
Materials and methods section and transformed into BL21
E. coli. The optimum expression condition of the recombinant
protein was found to be 0.8 mM IPTG at 37°C for 6 hours.
The molecular weight of the expressed protein was estimated to be approximately 27 kDa, suggesting a correct
size of typical rSPA protein. Immunoblotting analysis demonstrated that the expressed protein specifically bound to
anti-rSPA polyclonal antibody at 27 kDa, whereas no band
was seen in a control GST protein (Figure 1A). ELISA also
showed robust binding activity between rSPA and goat antirSPA-poly-ant compared to the control protein (Figure 1B).
Overall data suggest that we successfully constructed,
produced, and purified rSPA.

Alpaca immunization, generation, and
screening of anti-rSPA nanobody library
An alpaca was immunized with the recombinant rSPA,
and blood serum was separated before each immunization.
Rabbit anti-alpaca IgG labeled with HRP was prepared as a
second antibody. Our results showed that the antibody titer
gradually increased with increasing immunization times,
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Figure 1 Detection of rSPA by Western immunoblot and ELISA.
Notes: (A) Western immunoblot showed the expressed rSPA (lane 2) can bind to a goat anti-rSPA polyclonal antibody compared to the negative control group (lane 1) at 27
kDa. (B) ELISA analysis showed a high binding activity of the expressed rSPA (lane 2) to anti-rSPA polyclonal antibody compared to the negative control (lane 1). *P0.05.
Abbreviations: rSPA, rat surfactant protein A; ELISA, enzyme-linked immunosorbent assay; OD, optical density.

and reached an effective concentration of 1:12,000 after the
fourth immunization (Table 1).
Lymphocytes were purified from 200 mL peripheral
blood of the rSPA-immunized alpaca and total messenger
RNA from 2.9×109 lymphocytes was extracted using Trizol
reagent to obtain cDNA. The VHH fragments with a size
of 500 bp were generated by polymerase chain-reaction
amplification. A V HH library with 5.93×10 5 fragments
was obtained. After three consecutive rounds of in vitro
panning using the rSPA antigen, phage particles, which
bound specifically to rSPA, were successfully enriched
(Table 2). A total of 31 random clones with high affinity for
rSPA were identified by phage ELISA. DNA-sequencing
analysis revealed that six clones among them were IgG2a
subtype, and 25 clones were IgG3 subtype (Figure 2A
and B). Cluster analysis showed that 31 individual clones
contained 16 different sequences, among which Nb17,
2, and 4 contained significant repeats (identical sequences),
and Nb12, 18, 8, and 20 and Nb6, 16, 25, and 7 contained

another two types of repeats, which indicated significant
enrichment of these three isotypes (Figure 2C). After
initial testing of binding specificity for the antigen, we
designated two of them (Nb17, Nb6) and performed further
characterization.

Production and binding specificity of
anti-rSPA nanobodies
Two clones, Nb6 and Nb17, were chosen for further characterization. Expression conditions of both sequences were
analyzed using various temperatures and IPTG concentrations. Optimal expression levels were attained at 25°C for
4 hours with 0.8 mM IPTG. The molecular weights of these
proteins were approximately 19 kDa and were soluble. The
concentration of the purified proteins was approximately
25 mg/mL. With immunoblotting, rSPA reacted well with purified Nb6 and Nb17 with a single band of 19 kDa (Figure 3A).
ELISA also showed that the purified Nb6 and Nb17 had
positive reactivity to rSPA (Figure 3B).

Table 1 Alpaca immune antibody titer
Immune frequency

Antibody titer
1:100

1:500

1:1,000

1:2,000

1:4,000

1:8,000

1:10,000

1:12,000

1
2

+

+

+

-

-

-

-

-

3

+

+

+

+

+

+

-

-

4
5

+
+

+
+

+
+

+
+

+
+

+
+

+
+

+
+

Notes: + is the ratio of antibody optical density value to the negative control, optical density value greater than or equal to 2.1, and - is less than 2.1.
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Table 2 Enrichment after three rounds of panning
Panning
round

Amount of coated
antigen (μg/mL)

Input number
of phages (cfu)

Output number
of phages (cfu)

Recovery
rate (%)

1
2
3

100
50
25

7.8×1014
5.3×1012
6.9×1012

4.3×105
2.5×106
2.1×107

5.5×10-7
4.7×10-4
3.0×10-3

To investigate further the binding ability of Nb6 and
Nb17 to naturally occurring rSPA, immunohistochemistry
was performed on cryosections of rat lung, heart, liver,
spleen, kidney, and muscle. Our results showed that both Nb6
and Nb17 preferentially bound to rat lung tissue (Figure 4,
brown staining), but did not show binding to the heart,
liver, spleen, kidney, or muscle, and the same-degree reaction with the lung tissues by anti-SPA-poly-ant (positive
control) was also detected. However, the binding ability of
Nb6 was weaker than that of Nb17 and anti-SPA-poly-ant
(Figure 4). No significant binding reaction was observed in
the negative-control group.
Since Nb17 showed a higher binding ability to rSPA in
immunohistochemistry than Nb6, we chose Nb17 to evaluate
its targeting ability further. In order to investigate the biophysical feature of Nb17, a standard antigen-specific ELISA was
performed to test whether binding could be observed at various
temperatures and various pH values. As shown in Figure 5,
contrary to conventional rSPA-poly-ant, Nb17 was found to
be far more stable. In more detail, for Nb17, it is clearly shown
that it specifically bound to rSPA even at temperatures of
90°C and pH values of 3.5 or at 8.0. However, rSPA-poly-ant
showed almost no antigen binding when the temperature was
above 70°C and acid or alkaline conditions were extreme.
We next performed QCM based on the frequency change
of quartz crystal resonance, which has been widely used to
characterize protein features, including protein–protein interaction. To confirm the specific binding of Nb17 to rSPA, an
irrelevant nanobody that did not recognize rSPA was generated and used as a negative control. As Figure 6A shows,
the frequency change of Nb17 (∆f17) was significantly higher
than that of the control nanobody (∆fCTR) by the passage of
time, indicating the high binding ability between Nb17 and
rSPA. These results suggest that our Nb17 possesses high
specificity for rSPA.

Analysis of the targeting ability of Nb17
in mice
We chose a mouse model for in vivo imaging to detect the
lung-targeting ability of Nb17, as rats have a high homology
(95%) to the mouse SPA amino acid sequence. As shown in
2862
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Figure 6B, we injected FITC-labeled Nb17 (FITC-Nb17) or
FITC-SPA-poly-ant (control). FITC-Nb17 began to accumulate in mouse lungs at 15 minutes after tail-vein injection, and
was almost completely cleared from the bladder at 6 hours
after injection. However, no concentrated FITC was detected
in any other organs. SPA-poly-ant also began to enter mouse
lungs at 15 minutes after intravenous injection, but its binding to rat lungs was much lower than that of the Nb17-FITC.
We labeled the protein according to the reaction between the
R-amino group on lysine of protein and carbon–sulfur bond
amine on fluorescence to form a FITC-protein conjugate
(fluorescence antibody). A whole IgG antibody has 86 lysine
residues, and 15–20 of them can be used for the reaction.
As a nanobody, Nb17’s size is only 10% of an IgG antibody,
so the overall fluorescence that can bind is much less than that
of a whole IgG antibody. FITC-SPA-poly-ant were also seen
in other organs at high concentration besides lungs, and almost
completely removed from the lungs and bladder of rats at
6 hours after injection. The free FITC group failed to show
organ-specific accumulation, and was completely cleared
from the kidney and the bladder of rats (data not shown).

Analysis of acute and chronic toxicity
Serum alanine transaminase, aspartate transaminase, blood
urea nitrogen, and serum creatinine were determined to assess
the acute (1-week) and chronic (3-month) toxicity in rats as
detailed earlier. No statistically significant differences were
found between any of the four groups by multiple-comparison
analysis (P0.05, Table 3). Therefore, overall data indicated
that Nb17 had not induced significant toxicity. We further
analyzed the histological alterations caused by Nb17 using
cryosections of the lung, liver, spleen, and kidney in acute
toxicity, chronic toxicity, and control groups. Our results
showed that there were no apparent histological alterations by
morphological assessment in tissues of the lung, liver, spleen,
or kidney of rats between the Nb17 groups and controls using
hematoxylin and eosin staining (Figure 7).

Discussion
Active targeting drugs are believed to have favorable
properties, such as concentrated drugs at the site of the
International Journal of Nanomedicine 2015:10
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No29 (–0.0015)
No38 (0.0015)
No46 (0.3898)

Figure 2 Nanobody sequencing analysis.
Notes: (A, B) The amino acid sequences encoded by phagemid clones. All 31 sequences were VHH sequences, in which five clones (Nb1, 43, 28, 48, 32) were an IgG2a subtype
and the remaining clones were an IgG3 subtype. Section 1 includes 1–96 amino acid sequences of all 31 sequences; section 2 includes 97–183 amino acid sequences of all 31
sequences. (C) Cluster analysis of amino acid sequences. The 31 individual clones contained 16 different sequences. Among them, Nb17, 2, and 4 were repeats (with many
identical sequences), Nb12, 18, 8, and 20 were repeats, and Nb6, 16, 25, and 7 were repeats as well. Identification of these repeats indicated the enrichment of these three
antibody isotypes.
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Figure 3 Analysis of the binding specificity of Nb6 and Nb17 to rSPA.
Notes: (A) Western blot showed that Nb6 (lane 1) and Nb17 (lane 2) bound to rSPA at 19 kDa, lane 3 are mark. (B) ELISA showed excellent binding activity of Nb6 (lane 1)
and Nb17 (lane 2)to rSPA compared to the negative control (lane 3). *P0.05.
Abbreviations: rSPA, rat surfactant protein A; ELISA, enzyme-linked immunosorbent assay; OD, optical density.
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2.0

Figure 4 Immunohistochemistry in vitro.
Notes: Immunohistochemistry with frozen sections of rat lungs and other organs showed that both Nb6 and Nb17 bound to the rat lung (brown coloration), but did not
bind to the heart, liver, spleen, kidney, or muscle. The positive-control group also stained well (magnification ×200, scale bar 50 μm).
Abbreviation: SPA-poly-ant, surfactant protein A polyclonal antibody.
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Figure 5 Biophysical analyses of Nb17.
Notes: Antigen-specific ELISA was performed to test the binding ability of Nb17, SPA-poly-ant at various temperatures (A) and at various pH (B).
Abbreviations: ELISA, enzyme-linked immunosorbent assay; SPA-poly-ant, surfactant protein A polyclonal antibody.

disease, enhanced therapeutic effects, reduced systemic side
effects, and lowered costs. However, development of active
lung-targeting drugs has been impeded by the difficulty in
identifying specific lung targets and their appropriate ligands.
Thus far, studies on lung targeting have been largely dependent on the mechanical retention of pulmonary capillary and
airway inhalation, in which both have intrinsic limitations.
To explore a new way for lung targeting, peptide targeting
to the pulmonary vasculature was developed by screening
phage-peptide libraries in vivo after intravenous injection into
the lungs of mice, due to the differences in vascular endothelial cells from different organs.31–33 However, this method has
met limited success in clinical application, in part because of
the increased risk of thrombosis. Therefore, it is necessary to
explore a more effective lung-targeting strategy.
rSPA is one of the most abundant pulmonary surfactant
proteins (SPs), and is expressed on alveolar epithelial type II
cells and Clara cells. In addition, rSPA messenger RNA can
also be detected in the epithelial cells of the middle ear, jejunum, colon, and serosa mesothelium, but in much lower protein levels.14 In our previous work, we also showed that rSPA
can serve as a lung-targeting molecule. However, natural SPA
cannot meet experimental requirements, since it is primarily
extracted from bronchoalveolar lavage fluid, and this procedure is associated with very complicated steps and a low yield.
In this study, we generated recombinant rSPA by a prokaryotic expression system, and successfully used the rSPA as an
immunogen to produce lung-targeting nanobodies.
Ligands for ideal lung targeting require not only a high
affinity to the target but also unique characteristics, including
low molecular weight, low immunogenicity, and high tissue
International Journal of Nanomedicine 2015:10

penetration. As the binding between antigen and antibody has
high affinity and stability, anti-SPA antibody may be suitable
for lung-targeting ligands. However, conventional antibodies
(such as a polyclonal and monoclonal antibodies) consisting
of two heavy and two light chains suffer from a number of
drawbacks, such as high molecular weight (150 kDa), high
immunogenicity, low tissue penetration, and high costs in
production. Recent technical advances have allowed the
transformation of those conventional antibody molecules into
small antibody molecules (eg, Fab and single-chain variable
fragments) through genetic engineering technology, but these
molecules are not satisfactory for specific ligands because of
their decreased stability and affinity to their antigens. Interestingly, these drawbacks of conventional antibodies may
be solved by using single-chain antibody fragments (VHHs or
nanobodies). A nanobody is the smallest antibody molecule,
with intact antigen-binding capability, strong stability, and
tissue penetration. Nanobodies have been applied in multiple
fields of medicine as a novel antibody drug.34–36 However,
there have been no reports of any anti-rSPA nanobodies for
lung-targeting ligands.
The ability to isolate a specific nanobody from immunized
phage libraries has been used by several groups.27–29 In the
present study, we successfully immunized an alpaca using
our recombinant rSPA, and constructed a size of 5.93×105
cfu immunized library. Fortunately, 31 clones with high
affinity for rSPA were successfully screened using a phage
ELISA. After DNA sequencing, 16 different VHH sequences
were obtained. Nanobodies are highly expressed in a variety of microorganisms, since they are encoded by a single
gene, small molecular weight, and simple structure.37–40
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Figure 6 Analysis of binding affinity and toxicity in the lung.
Notes: (A) Binding-ability analysis of Nb17 by quartz crystal microbalance. The maximum frequency change of Nb17 (∆f17 =190 HZ) was significantly higher than the control
(CTR) (∆fCTR =30 HZ). This indicated that the binding specificity of Nb17 to rSPA was significantly higher than that of the control nanobody. (B) Lung-targeted analysis of
Nb17 in vivo in nude mice. The experiments were performed independently three times, and showed similar results.
Abbreviations: FITC, fluorescein isothiocyanate; rSPA, rat surfactant protein A; poly-ant, polyclonal antibody.

Table 3 Liver- and kidney-function test
Group

ALT (IU/L)

AST (IU/L)

BUN (mmol/L)

Cr (μmol/L)

Acute
Acute-negative
Chronic
Chronic-negative

66.30±15.34
63.40±18.94
64.30±14.14
65.40±13.77

190.05±30.06
185.32±24.38
178.05±23.12
188.05±24.25

5.10±1.07
6.16±1.52
5.78±2.03
6.02±1.82

18.97±4.06
19.78±5.73
19.07±3.82
20.08±4.62

Note: All values showed in the table are in mean ± SD.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; Cr, creatinine.
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Figure 7 Histological analysis of rat lungs, liver, spleen, kidneys by hematoxylin and eosin staining.
Notes: Different reagents (Nb17 or control antibodies) were administered to rats for acute (1 week) or chronic (3 months) toxicity study. Then, the lung, liver, spleen, and
kidney tissues were processed for hematoxylin and eosin staining.
Abbreviation: Neg, negative.

The methods for preparation of nanobodies are straightforward compared to the procedures for genetic engineering
antibody preparation. The two nanobodies (Nb6 and Nb17)
in our current study also can be routinely prepared under
normal culture conditions, establishing a simple and efficient
approach for nanobody preparation.
The binding ability of the nanobodies (Nb6 and Nb17)
with rSPA was assessed and validated by immunoblotting
and ELISA. Our data indicated that both Nb6 and Nb17
can specifically bind to naturally occurring rSPA. Using
immunohistochemistry, the binding ability of Nb17 was
as strong as the positive-control group (a commercial antiSPA-poly-ant), while Nb6 was relatively weak. One possible
explanation for this phenomenon is that in spite of the high
degree of similarity between the sequences of Nb17 and Nb6,
a tiny difference in variable region contributes enormously
to binding strengths.
When antibodies were tested for functional binding at
various temperatures and at various pH conditions to their
antigen, major differences were observed between the Nb17

International Journal of Nanomedicine 2015:10

and rSPA-poly-ant. It is possible that the extreme conditions
resulted in dissociation of the polyantibody structure, thereby
exposing the hydrophobic interfaces on both heavy and light
chains. The exposed hydrophobic interfaces subsequently
aggregated and precipitated, resulting in nonfunctional
molecules. However, contrary to conventional antibodies,
because of the efficient refolding after chemical or thermal
denaturation of nanobodies and an additional disulfide bond
between complementary determining regions CDR1 and
CDR3, improved protein stability can be obtained.41,42
To determine further the lung-targeting ability of the
recombinant nanobody, we performed in vivo imaging by
labeling Nb17 with FITC (FITC-Nb17). FITC-Nb17 began
to accumulate in the lung at 15 minutes after intravenous
injection, but was completely metabolized by the kidney
and bladder at 6 hours after injection. Compared to SPApoly-ant, FITC-Nb17 had much higher accumulation and
longer retention in the lung. Importantly, no obvious accumulation of free FITC (a negative control) was detected in
any organs. This finding strongly suggests not only strong
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lung-targeting capability for Nb17 but also limited retention
in the liver and spleen. Although it is impossible to have
no cross-reactivity, background retention in those organs
appeared to be minimal.
In addition to analyzing in vivo biodistribution, we also
carried out acute and chronic toxicity tests with the anti-rSPA
nanobodies. Our results confirmed the safety of the nanobodies in rats, which is consistent with previous reports.43 In fact,
the nanobodies had small molecular weights with only one
domain and without an Fc domain of a traditional antibody,
thus avoiding complement activation caused by the Fc domain.
Additionally, the nanobodies bore a high degree of homology
with the human VH gene-family sequence, which may contribute to their low immunogenicity and high safety profile in the
context of using nanobodies in future clinical therapeutics.
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